Get notified when ORKA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Entities Affiliated With Fairmount Funds Management Llc Beneficially Own 20,431,075 Shares of Our Common Stock, or Approximately 35.2% (new) — A single investor group holds over a third of the company's voting power, which could lead to significant influence over corporate decisions and potential conflicts of interest.
- If You Purchase Our Securities In This Offering, You Will Incur Immediate and Substantial Dilution (new) — The offering price is substantially above net tangible book value per share, causing immediate and substantial dilution to new investors.
Oruka Therapeutics files 424B5 for common stock and pre-funded warrant offering; pricing terms left blank
Filed April 27, 2026 · ~1 min read
Key Changes
-
high
Oruka Therapeutics is offering common stock and pre-funded warrants, but the number of shares and offering price are not specified in the prospectus supplement.
The Offering verify on EDGAR → -
medium
Underwriters have a 30-day option to purchase up to an additional $75 million of common stock, which could increase dilution.
The Offering verify on EDGAR → -
medium
Net proceeds will be used for general corporate purposes, including research and development and working capital, with management retaining broad discretion.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade ORKA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify